CytoReason vs Ikko Health
CytoReason vs Ikko Health, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Ikko Health on 45/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 45/100
- headcount: 116 against 15
- funding raised: $128M against $1.0M
- LinkedIn following: 12,830 against 67
Ikko Health
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CytoReason | Ikko Health |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Transforming healthcare by turning scientific fiction into scientific facts. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, HealthTech, MedTech, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Platform |
| Founded | 2016 | 2021 |
| Headquarters | Tel Aviv, Israel | London, United Kingdom |
| Status | Active | Inactive |
Size, funding and growth
| Measure | CytoReason | Ikko Health |
|---|---|---|
| Employees | 116 | 15 |
| Headcount growthLast 12 months | +13.7% | +12.7% |
| Total funding | $128M | $1.0M |
| Latest round | Series B | Seed |
| LinkedIn followers | 12,830 | 67 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Ikko Health |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 45/100 |
| Traction | 60/100 | 42/100 |
| Team | 70/100 | 50/100 |
| Search visibility | 30/100 | 25/100 |
| Quality | 78/100 | 48/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 40/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Ikko Health |
|---|---|---|
| Analytics | Segment | Not detected |
CytoReason vs Ikko Health: common questions
Which is better, CytoReason or Ikko Health?
On our 0-100 score CytoReason rates higher (68/100 against 45/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do CytoReason and Ikko Health compare on the numbers?
CytoReason leads on our overall score (68/100 against 45/100), headcount (116 against 15), funding raised ($128M against $1.0M), LinkedIn following (12,830 against 67).
Read the full CytoReason review and pricing or the Ikko Health review and pricing. You can also browse other CytoReason alternatives we track.